177Lu-R11228 / Radionetics Oncology - LARVOL DELTA

A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer (clinicaltrials.gov) - P1 | N=11 | Terminated | Sponsor: Radionetics Oncology | N=62 ➔ 11 | Trial completion date: Jun 2033 ➔ Jun 2026 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2028 ➔ Jun 2026; Sponsor decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PGR

A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer (clinicaltrials.gov) - P1 | N=62 | Recruiting | Sponsor: Radionetics Oncology | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer (clinicaltrials.gov) - P1 | N=62 | Not yet recruiting | Sponsor: Radionetics Oncology

New P1 trial • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor